Feasibility evaluation of low-crystallinity β-tricalcium phosphate blocks as a bone substitute fabricated by a dissolution–precipitation reaction from α-tricalcium phosphate blocks

Garima Tripathi, Yuki Sugiura, Aivaras Kareiva, Edita Garskaite, Kanji Tsuru, Kunio Ishikawa

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Although sintered β-tricalcium phosphate blocks have been used clinically as artificial bone substitutes, the crystallinity of β-tricalcium phosphate, which might dominate biocompatibility, is extremely high. The objective of this study is to evaluate the feasibility of fabricating low-crystallinity β-tricalcium phosphate blocks, which are expected to exhibit good biocompatibility via a dissolution–precipitation reaction of α-tricalcium phosphate blocks as a precursor under hydrothermal conditions at 200°C for 24 h. Although β-tricalcium phosphate is a metastable phase, the presence of Mg2+ in the reaction solution inhibits the formation of its corresponding stable phase and induces β-tricalcium phosphate formation under acidic conditions. It was found that low-crystallinity β-tricalcium phosphate blocks could be fabricated from α-tricalcium phosphate blocks immersed in 1.0 mol/L MgCl2 + 0.1 mol/L NaH2PO4 solution while maintaining the shape of the α-tricalcium phosphate blocks. The crystallite size of the fabricated β-tricalcium phosphate blocks was 42 nm, which was substantially smaller than that of the sintered β-tricalcium phosphate blocks. When the fabricated β-tricalcium phosphate blocks were implanted into bone defects in rabbit femurs, they exhibited excellent tissue responses. In particular, the initial osteoconductivity (two and four weeks) was substantially greater than that of sintered β-tricalcium phosphate blocks.

Original languageEnglish
Pages (from-to)259-270
Number of pages12
JournalJournal of Biomaterials Applications
Volume33
Issue number2
DOIs
Publication statusPublished - Aug 1 2018

Fingerprint

Bone Substitutes
Bone
Phosphates
Biocompatibility
tricalcium phosphate
Magnesium Chloride
Metastable phases
Crystallite size

All Science Journal Classification (ASJC) codes

  • Biomaterials
  • Biomedical Engineering

Cite this

Feasibility evaluation of low-crystallinity β-tricalcium phosphate blocks as a bone substitute fabricated by a dissolution–precipitation reaction from α-tricalcium phosphate blocks. / Tripathi, Garima; Sugiura, Yuki; Kareiva, Aivaras; Garskaite, Edita; Tsuru, Kanji; Ishikawa, Kunio.

In: Journal of Biomaterials Applications, Vol. 33, No. 2, 01.08.2018, p. 259-270.

Research output: Contribution to journalArticle

@article{101cd0e3d2c146b88fd4691d234f643a,
title = "Feasibility evaluation of low-crystallinity β-tricalcium phosphate blocks as a bone substitute fabricated by a dissolution–precipitation reaction from α-tricalcium phosphate blocks",
abstract = "Although sintered β-tricalcium phosphate blocks have been used clinically as artificial bone substitutes, the crystallinity of β-tricalcium phosphate, which might dominate biocompatibility, is extremely high. The objective of this study is to evaluate the feasibility of fabricating low-crystallinity β-tricalcium phosphate blocks, which are expected to exhibit good biocompatibility via a dissolution–precipitation reaction of α-tricalcium phosphate blocks as a precursor under hydrothermal conditions at 200°C for 24 h. Although β-tricalcium phosphate is a metastable phase, the presence of Mg2+ in the reaction solution inhibits the formation of its corresponding stable phase and induces β-tricalcium phosphate formation under acidic conditions. It was found that low-crystallinity β-tricalcium phosphate blocks could be fabricated from α-tricalcium phosphate blocks immersed in 1.0 mol/L MgCl2 + 0.1 mol/L NaH2PO4 solution while maintaining the shape of the α-tricalcium phosphate blocks. The crystallite size of the fabricated β-tricalcium phosphate blocks was 42 nm, which was substantially smaller than that of the sintered β-tricalcium phosphate blocks. When the fabricated β-tricalcium phosphate blocks were implanted into bone defects in rabbit femurs, they exhibited excellent tissue responses. In particular, the initial osteoconductivity (two and four weeks) was substantially greater than that of sintered β-tricalcium phosphate blocks.",
author = "Garima Tripathi and Yuki Sugiura and Aivaras Kareiva and Edita Garskaite and Kanji Tsuru and Kunio Ishikawa",
year = "2018",
month = "8",
day = "1",
doi = "10.1177/0885328218788255",
language = "English",
volume = "33",
pages = "259--270",
journal = "Journal of Biomaterials Applications",
issn = "0885-3282",
publisher = "SAGE Publications Ltd",
number = "2",

}

TY - JOUR

T1 - Feasibility evaluation of low-crystallinity β-tricalcium phosphate blocks as a bone substitute fabricated by a dissolution–precipitation reaction from α-tricalcium phosphate blocks

AU - Tripathi, Garima

AU - Sugiura, Yuki

AU - Kareiva, Aivaras

AU - Garskaite, Edita

AU - Tsuru, Kanji

AU - Ishikawa, Kunio

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Although sintered β-tricalcium phosphate blocks have been used clinically as artificial bone substitutes, the crystallinity of β-tricalcium phosphate, which might dominate biocompatibility, is extremely high. The objective of this study is to evaluate the feasibility of fabricating low-crystallinity β-tricalcium phosphate blocks, which are expected to exhibit good biocompatibility via a dissolution–precipitation reaction of α-tricalcium phosphate blocks as a precursor under hydrothermal conditions at 200°C for 24 h. Although β-tricalcium phosphate is a metastable phase, the presence of Mg2+ in the reaction solution inhibits the formation of its corresponding stable phase and induces β-tricalcium phosphate formation under acidic conditions. It was found that low-crystallinity β-tricalcium phosphate blocks could be fabricated from α-tricalcium phosphate blocks immersed in 1.0 mol/L MgCl2 + 0.1 mol/L NaH2PO4 solution while maintaining the shape of the α-tricalcium phosphate blocks. The crystallite size of the fabricated β-tricalcium phosphate blocks was 42 nm, which was substantially smaller than that of the sintered β-tricalcium phosphate blocks. When the fabricated β-tricalcium phosphate blocks were implanted into bone defects in rabbit femurs, they exhibited excellent tissue responses. In particular, the initial osteoconductivity (two and four weeks) was substantially greater than that of sintered β-tricalcium phosphate blocks.

AB - Although sintered β-tricalcium phosphate blocks have been used clinically as artificial bone substitutes, the crystallinity of β-tricalcium phosphate, which might dominate biocompatibility, is extremely high. The objective of this study is to evaluate the feasibility of fabricating low-crystallinity β-tricalcium phosphate blocks, which are expected to exhibit good biocompatibility via a dissolution–precipitation reaction of α-tricalcium phosphate blocks as a precursor under hydrothermal conditions at 200°C for 24 h. Although β-tricalcium phosphate is a metastable phase, the presence of Mg2+ in the reaction solution inhibits the formation of its corresponding stable phase and induces β-tricalcium phosphate formation under acidic conditions. It was found that low-crystallinity β-tricalcium phosphate blocks could be fabricated from α-tricalcium phosphate blocks immersed in 1.0 mol/L MgCl2 + 0.1 mol/L NaH2PO4 solution while maintaining the shape of the α-tricalcium phosphate blocks. The crystallite size of the fabricated β-tricalcium phosphate blocks was 42 nm, which was substantially smaller than that of the sintered β-tricalcium phosphate blocks. When the fabricated β-tricalcium phosphate blocks were implanted into bone defects in rabbit femurs, they exhibited excellent tissue responses. In particular, the initial osteoconductivity (two and four weeks) was substantially greater than that of sintered β-tricalcium phosphate blocks.

UR - http://www.scopus.com/inward/record.url?scp=85050529212&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050529212&partnerID=8YFLogxK

U2 - 10.1177/0885328218788255

DO - 10.1177/0885328218788255

M3 - Article

VL - 33

SP - 259

EP - 270

JO - Journal of Biomaterials Applications

JF - Journal of Biomaterials Applications

SN - 0885-3282

IS - 2

ER -